Clark Golestani - Merck Executive Vice President CIO

MRK Stock  MXN 2,165  98.07  4.74%   

President

Mr. Clark Golestani is Executive Vice President, Chief Information Officer of Merck Co., Inc. He is responsible for Mercks global information technology . His experience includes August 2008 Vice President, Merck Research Laboratories Information Technology, Merck Co., Inc. responsible for global IT for Mercks Research Development division, including Basic Research, PreClinical, Clinical and Regulatory from November 2006 Vice President, Corporationrationrate Information Technology, Merck Co., Inc. responsible for global IT supporting Finance, Human Resources, Procurement, Legal, Public Affairs, Site Services, Real Estate, and Shared Business Services operations. since 2012.
Age 48
Tenure 12 years
Phone908 740 4000
Webhttps://www.merck.com

Merck Management Efficiency

The company has return on total asset (ROA) of 0.1268 % which means that it generated a profit of $0.1268 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.351 %, meaning that it generated $0.351 on every $100 dollars invested by stockholders. Merck's management efficiency ratios could be used to measure how well Merck manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 30.69 B in total debt with debt to equity ratio (D/E) of 99.4, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Merck Company has a current ratio of 1.19, suggesting that it may not be capable to disburse its financial obligations in time and when they become due. Debt can assist Merck until it has trouble settling it off, either with new capital or with free cash flow. So, Merck's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Merck Company sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Merck to invest in growth at high rates of return. When we think about Merck's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

PRESIDENT Age

Michael WassmerCapital One Financial
53
Rima QureshiVerizon Communications
53
Gregory HartUnited Airlines Holdings
52
Anthony SkiadasVerizon Communications
48
John StrattonVerizon Communications
55
Brady ConnorVerizon Communications
N/A
Kleber SantosCapital One Financial
44
Matthew EllisVerizon Communications
52
Richard CorradoAir Transport Services
63
Mike StefanskiVerizon Communications
N/A
Marni WaldenVerizon Communications
48
Michael SlocumCapital One Financial
61
Hans VestbergVerizon Communications
58
Chris BartlettVerizon Communications
N/A
Chris KennyUnited Airlines Holdings
53
Darren AlcusCapital One Financial
N/A
Ronan DunneVerizon Communications
N/A
William PayneAir Transport Services
53
Irene FoxhallUnited Airlines Holdings
62
Andrew LevyUnited Airlines Holdings
46
Jonathan WitterCapital One Financial
46
It operates through four segments Pharmaceutical, Animal Health, Healthcare Services, and Alliances. Merck Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey. MERCK INC operates under Drug Manufacturers - Major classification in Mexico and is traded on Mexico Stock Exchange. It employs 69000 people. Merck Company (MRK) is traded on Mexican Exchange in Mexico and employs 44 people.

Management Performance

Merck Company Leadership Team

Elected by the shareholders, the Merck's board of directors comprises two types of representatives: Merck inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Merck. The board's role is to monitor Merck's management team and ensure that shareholders' interests are well served. Merck's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Merck's outside directors are responsible for providing unbiased perspectives on the board's policies.
Thomas Glocer, Independent Director
Craig Thompson, Independent Director
Cristal Downing, Ex Officer
Jennifer Zachary, General Counsel
Rochelle Lazarus, Independent Director
Michael Rosenblatt, Executive Vice President Chief Medical Officer
Wendell Weeks, Independent Director
Michael Holston, Executive Vice President Chief Ethics and Compliance Officer
Paul Rothman, Director
Mary Coe, Director
Adele Ambrose, Senior Vice President Chief Communications Officer
Caroline Litchfield, Ex CFO
Joseph Romanelli, IR Contact Officer
Mirian GraddickWeir, Executive Vice President - Human Resources
Peter Wendell, Independent Director
John Noseworthy, Independent Director
Jennifer Mauer, VP Communications
Leslie Brun, Independent Director
Julie Gerberding, Executive Vice President - Strategic Communications, Global Public Policy & Population Health
Inge Thulin, Director
Pamela Craig, Director
Patricia Russo, Independent Director
David Williams, Ex Officer
Willie Deese, Executive Vice President and Presidentident - Merck Manufacturing Division
Rita Karachun, Principal Accounting Officer, Sr. VP of Fin. and Global Controller
Lisa LeCointeCephas, VP Officer
Robert Davis, CFO and Executive VP
Robert Kidder, Independent Director
Thomas Cech, Independent Director
Michael Nally, Chief Marketing Officer
Peter Dannenbaum, VP Relations
Clark Golestani, Executive Vice President CIO
William Harrison, Lead Independent Director
Roger Perlmutter, Executive Vice President and Presidentident - Merck Research Laboratories
Ashley Watson, Senior Vice President Chief Ethics and Compliance Officer
Steven Mizell, Chief Human Resource Officer
Jim Scholefield, Chief Information and Digital Officer
Sanat Chattopadhyay, Executive Vice President and President - Merck Manufacturing Division
Adam Schechter, President of Global Human Health and Executive VP
Carlos Represas, Independent Director
Richard DeLuca, Executive Vice President and Presidentident - Merck Animal Health
Kenneth Frazier, Chairman, CEO and Pres
Frank Clyburn, Chief Commercial Officer
Robert JD, Pres Chairman

Merck Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Merck a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Merck in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Merck's short interest history, or implied volatility extrapolated from Merck options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Merck Company is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Merck Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Merck Company Stock. Highlighted below are key reports to facilitate an investment decision about Merck Company Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..

Complementary Tools for Merck Stock analysis

When running Merck's price analysis, check to measure Merck's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merck is operating at the current time. Most of Merck's value examination focuses on studying past and present price action to predict the probability of Merck's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merck's price. Additionally, you may evaluate how the addition of Merck to your portfolios can decrease your overall portfolio volatility.
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Money Managers
Screen money managers from public funds and ETFs managed around the world
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Commodity Directory
Find actively traded commodities issued by global exchanges
Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine if Merck is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.